BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 12, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

RNA illustration

Sirnaomics starts 2022 with $64M Hong Kong IPO

Jan. 4, 2022
By Doris Yu
Sirnaomics Ltd. became the first RNA therapeutics company to list on the Hong Kong Stock Exchange (HKEX) with a $64 million initial public offering. Its shares (HKEX:2277) have since surged, rising to HK$93.90 ($12.04) on Jan. 4 following their debut at HK$65.90 per share.
Read More

Financings for Jan. 4, 2022

Jan. 4, 2022
Biopharmas in Asia-Pacific raising money in public or private financings: Biondvax, Genfleet.
Read More

Financings for Jan. 4, 2022

Jan. 4, 2022
Med-tech firms raising money in public or private financings, including: Strados Labs, Moleculight.
Read More

Xuanzhu Biopharm raises $96M in series B round to fund phase III trials

Jan. 4, 2022
By Doris Yu
Sihuan Pharmaceutical Holdings Group Ltd.’s subsidiary Xuanzhu Biopharmaceutical Co. Ltd. has raised ¥610.5 million ($96 million) in a series B round led by Sunshine Life Insurance Corp. Ltd.
Read More
Flags of Denmark, Sweden, Finland and Norway

Scandinavian VC fund raises $124M for focus on rare diseases

Jan. 4, 2022
By Nuala Moran
LONDON – Novo Holdings has inspired the formation of the second new fund in 18 months aiming to feed more capital into the commercialization of Scandinavian science, acting as cornerstone investor in Sound Bioventures Fund I. The new fund greeted the New Year with a first close of €110 million (US$124 million), to be invested in private biopharmas with late preclinical or clinical programs, primarily in rare diseases.
Read More

Financings for Jan. 4, 2022

Jan. 4, 2022
Biopharmas raising money in public or private financings, including: Amberstone, Amylyx, Aravive, Chance, Cincor, Intra-Cellular, Ray, Spectrum, TG, Vigil, Xeris.
Read More

Financings for Dec. 31, 2021

Dec. 31, 2021
Biopharmas raising money in public or private financings, including: Akari, Genfleet.
Read More
Rocket launch illustration

The Israeli incubator nurturing the next generation of med-tech innovation

Dec. 30, 2021
By Catherine Longworth
The need to develop advanced medical technologies is ever increasing, and one incubator is on a mission to identify the world’s most promising opportunities. In cooperation with partners including Israel Innovation Authority, Israeli incubator Medx Xelerator LP is expanding a portfolio of startups that are attacking some of health care’s biggest challenges.
Read More

Financings for Dec. 30, 2021

Dec. 30, 2021
Biopharmas raising money in public or private financings, including: Aeon, Biondvax, Proqr, Noxxon.
Read More

Financings for Dec. 29, 2021

Dec. 29, 2021
Biopharmas raising money in public or private financings, including: Enbiotix.
Read More
Previous 1 2 … 405 406 407 408 409 410 411 412 413 … 664 665 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 10, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent

    BioWorld Science
    Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing